MapLight Therapeutics, Inc. Common Stock Asset Resilience Ratio
MapLight Therapeutics, Inc. Common Stock asset resilience ratio. MapLight Therapeutics, Inc. Common Stock (MPLT) has an Asset Resilience Ratio of 63.28% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See MPLT defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of MapLight Therapeutics, Inc. Common Stock (2024–2025)
Asset resilience ratio of MapLight Therapeutics, Inc. Common Stock from 2024 to 2025. This chart shows how MapLight Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read MapLight Therapeutics, Inc. Common Stock balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down MapLight Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of MapLight Therapeutics, Inc. Common Stock.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $233.09 Million | 63.28% |
| Total Liquid Assets | $233.09 Million | 63.28% |
Asset Resilience Insights
- Very High Liquidity: MapLight Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 63.28% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
MapLight Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare MapLight Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
MapLight Therapeutics, Inc. Common Stock Asset Resilience Ratio by Year (2024–2025)
MapLight Therapeutics, Inc. Common Stock asset resilience ratio by year from 2024 to 2025. The table below shows the annual Asset Resilience Ratio data for MapLight Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 53.88% | $258.37 Million | $479.51 Million | +2.36pp |
| 2024-12-31 | 51.52% | $70.54 Million | $136.92 Million | -- |
About MapLight Therapeutics, Inc. Common Stock
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irrit… Read more